Investment Analysts’ Recent Ratings Updates for Revolution Medicines (RVMD)

Several brokerages have updated their recommendations and price targets on shares of Revolution Medicines (NASDAQ: RVMD) in the last few weeks:

• 10/17/2025 – Revolution Medicines was given a new $80.00 price target on by analysts at National Bankshares, Inc..
• 10/17/2025 – Revolution Medicines had its price target raised by analysts at Raymond James Financial, Inc. from $72.00 to $76.00. They now have a “strong-buy” rating on the stock.
• 10/17/2025 – Revolution Medicines had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $77.00 price target on the stock.
• 10/15/2025 – Revolution Medicines is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $85.00 price target on the stock.
• 10/8/2025 – Revolution Medicines had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Revolution Medicines had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/12/2025 – Revolution Medicines had its price target raised by analysts at The Goldman Sachs Group, Inc. from $65.00 to $73.00. They now have a “buy” rating on the stock.
• 9/12/2025 – Revolution Medicines is now covered by analysts at Raymond James Financial, Inc.. They set a “strong-buy” rating and a $72.00 price target on the stock.
• 9/11/2025 – Revolution Medicines had its price target raised by analysts at Wells Fargo & Company from $67.00 to $70.00. They now have an “overweight” rating on the stock.
• 9/11/2025 – Revolution Medicines had its price target raised by analysts at Wedbush from $73.00 to $77.00. They now have an “outperform” rating on the stock.
• 9/11/2025 – Revolution Medicines had its price target raised by analysts at Needham & Company LLC from $56.00 to $66.00. They now have a “buy” rating on the stock.
• 9/5/2025 – Revolution Medicines is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $99.00 price target on the stock.

Insider Buying and Selling at Revolution Medicines

In related news, CFO Jack Anders sold 2,320 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $45.82, for a total transaction of $106,302.40. Following the sale, the chief financial officer directly owned 110,994 shares of the company’s stock, valued at $5,085,745.08. This trade represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Margaret A. Horn sold 4,775 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $45.82, for a total value of $218,790.50. Following the completion of the transaction, the chief operating officer directly owned 145,900 shares of the company’s stock, valued at approximately $6,685,138. This trade represents a 3.17% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 188,033 shares of company stock worth $8,456,208. Insiders own 8.20% of the company’s stock.

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.